home / stock / argnf / argnf short
Short Information | Argen X NV (OTCMKTS:ARGNF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 48,925 |
Total Actual Volume | 49,036 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 16 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 2,446 |
Average Short Percentage | 84.02% |
Is there a ARGNF Short Squeeze or Breakout about to happen?
See the ARGNF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
06-27-2024 | $0 | $373.5 | $0 | $0 | 10,000 | 10,000 | 100% |
06-24-2024 | $0 | $373.5 | $0 | $0 | 20,000 | 20,000 | 100% |
06-05-2024 | $0 | $373.5 | $0 | $0 | 129 | 129 | 100% |
04-18-2024 | $0 | $383.74 | $0 | $0 | 136 | 136 | 100% |
12-22-2023 | $371 | $371 | $371 | $371 | 19 | 19 | 100% |
12-20-2023 | $428.6 | $341 | $428.6 | $341 | 3 | 1 | 33.33% |
11-10-2023 | $505 | $505 | $505 | $505 | 5 | 5 | 100% |
06-10-2022 | $335 | $335 | $335 | $335 | 30 | 30 | 100% |
05-09-2022 | $293.5 | $290 | $293.5 | $290 | 206 | 97 | 47.09% |
05-06-2022 | $308.15 | $312.75 | $312.75 | $308.15 | 42 | 42 | 100% |
03-19-2021 | $309 | $309 | $309 | $309 | 1 | 1 | 100% |
07-08-2020 | $248.6 | $248.6 | $248.6 | $248.6 | 129 | 129 | 100% |
01-13-2020 | $161.96 | $161.96 | $161.96 | $161.96 | 13,300 | 13,300 | 100% |
12-02-2019 | $N/A | $128.24 | $N/A | $N/A | 4 | 4 | 100% |
11-12-2019 | $128.24 | $128.24 | $128.24 | $128.24 | 5,000 | 5,000 | 100% |
05-03-2018 | $N/A | $85.00 | $N/A | $N/A | 25 | 25 | 100% |
04-10-2018 | $N/A | $85.00 | $N/A | $N/A | 4 | 4 | 100% |
04-05-2018 | $N/A | $85.00 | $N/A | $N/A | 3 | 3 | 100% |
News, Short Squeeze, Breakout and More Instantly...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART®...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlighting long-term commi...